The expanded approval intensifies the rivalry with Jazz Pharmaceuticals, which has previously attempted to block Lumryz’s ...

Avadel Pharmaceuticals plc AVDL announced that the FDA has approved its supplemental new drug application (sNDA) seeking ...

Lumryz is the only FDA-approved once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in children ...

Shares of Jazz Pharmaceuticals are trading only slightly higher in the last few weeks despite two unexpected wins. Explore ...

Avadel's drug contains a central nervous system depressant drug called sodium oxybate, which helps increase the amount of ...

The narcolepsy market is undergoing significant changes as new treatment strategies and product innovations emerge. Our newly ...

Avadel Pharmaceuticals has won expanded Food and Drug Administration approval of its narcolepsy drug Lumryz for use in children. Avadel on Thursday said the FDA nod covers Lumryz for the treatment of ...

Lumryz is an extended-release formulation of sodium oxybate, a central nervous system (CNS) depressant. Its therapeutic effects are believed to be mediated through GABA B actions at noradrenergic and ...

Sharron McSherry was just 14 when she kept falling asleep in school - it wasn't until many years later that she was diagnosed ...

Biopharmaceutical company Avadel Pharmaceuticals plc (AVDL), Thursday announced that the U.S. Food and Drug Administration (FDA) has ...

A series about how people with highly specific sleeping situations fall asleep and stay asleep — and the products they use. Dawn Super frequently naps in her car. She was diagnosed with ...

Narcolepsy is a chronic neurological disorder that disrupts the brain’s ability to regulate sleep-wake cycles, often leading ...